The effects of mirtazapine on plasma lipid profiles in healthy subjects

Journal of Clinical Psychiatry

Volumn 64, Issue 8, 2003, Pages 883-889

  Nicholas, Linda M ^a   Ford, Amy L ^b   Esposito, Sharon M ^b   Ekstrom, R David ^b   Golden, Robert N ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MIRTAZAPINE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 0042513494     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0805     Document Type: Article

References (18)

1. Golden RN, Dawkins K, Nicholas L, et al. Trazodone, nefazodone, bupropion, and mirtazapine. In: Nemeroff C, Schatzberg A, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:251-270
2. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996;5:389-402
3. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Non-Patient Edition (SCID-I/NP, 11/2002 revision). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002
4. Spitzer RL, Endicott J. The Schedule for Affective Disorders and Schizophrenia. 3rd ed. New York, NY: New York State Psychiatric Institute; 1978
5. Remeron [package insert]. West Orange, NJ: Organon Inc; 1998
6. Yeragani VK, Pohl R, Balon R, et al. Increased serum total cholesterol to HDL-cholesterol ratio after imipramine. Psychiatry Res 1990;32:207-209
7. Othmer E, Othmer SC, Stern WC, et al. Long-term efficacy and safety of bupropion. J Clin Psychiatry 1983;44:153-156
8. Pollock BG, Perel JM, Paradis CF, et al. Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacol Bull 1994;30:145-150
9. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97:24S-32S
10. Maes M, Smith R, Christophe A, et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immuneinflammatory markers. Acta Psychiatr Scand 1997;95:212-221
11. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994;11:105-111
12. de Zwaan M, Nutzinger DO. Effect of fluvoxamine on total serum cholesterol levels during weight reduction. J Clin Psychiatry 1996;57:346-348
13. Sullivan PF, Joyce PR, Bulik CM, et al. Total cholesterol and suicidality in depression. Biol Psychiatry 1994;37:472-477
14. Golier JA, Marzuk PM, Leon AC, et al. Low serum cholesterol level and attempted suicide. Am J Psychiatry 1995;152:419-423
15. Muldoon MF, Rossouw JE, Manuck SB, et al. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism 1993;42(9 suppl 1):45-46
16. Morgan RE, Palinkas LA, Barrett-Connor EL, et al. Plasma cholesterol and depressive symptoms in older men. Lancet 1993;341:75-79
17. Hibbeln JR, Salem N Jr. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995;62:1-9
18. Goodnick P, Kremer C, Wingard P. Weight change during mirtazapine therapy. Primary Psychiatry 1999;5:103-108